A study of clinical/biological markers of exacerbation/progression in a cohort of patients admitted with acute excerbation of COPD
DOI:
https://doi.org/10.18203/2349-3933.ijam20175539Keywords:
Biomarkers, COPD, Exacerbation, Pulmonary function test, SmokingAbstract
Background:Exacerbations of chronic obstructive pulmonary disease increases the morbidity, hospital admissions, mortality, and strongly influence health-related quality of life. The aims of this study to know the Clinical profile of COPD and acute exacerbation, Role of clinical markers in diagnosis and follow up of exacerbation.
Methods: A prospective study of a cohort of 60 patients hospitalized for AECOPD was undertaken to identify markers for frequent exacerbation and progression of disease. Advised to fill the SGRQ questionnaire, At the time of discharge 6MWT done and analyzed. C Reactive protein levels at the time of admission done and analyzed. Sputum grams stain culture, total counts and differential counts done and analyzed. At the time of discharge spirometry done both pre and post bronchodilators by using asthalin inhaler with or without spacer, results were analyzed.
Results:There was statistically significant drop in the SPO2 levels in frequent exacerbators over 6 months follow up time. There was statistically significant elevation of sputum Neutrophil counts in frequent exacerbators and Eosinophil counts in infrequent exacerbators, there was a drop in the CRP levels of from the time of initial exacerbation to 6 months follow up time. There was statistically significant drop in FEV1 in frequent exacerbators over 6 months follow up study. The drop of 6MWT was more in patients, who had frequent exacerbations.
Conclusions:Patients with more frequent exacerbation have more symptoms, drop in the saturation level and have more sputum neutrophil counts. Patients with more frequent exacerbations will have more deterioration of lung functions (FEV1.6MWT).
References
Jindal SK. A field study on follow up at 10 years of prevalence of chronic obstructive pulmonary disease and peak expiratory flow rate. Indian J Med Res. 1993;98:20-2.
Lundbäck B, Lindberg A, Lindström M, Rönmark E, Jonsson AC, Jönsson E, Larsson LG, Andersson S, Sandström T, Larsson K. Not 15 but 50% of smokers develop COPD?-report from the obstructive lung disease in Northern Sweden studies. Res Medic. 2003;97(2):115-22.
Claudia G, Cote LJ, Dordelly, Bartolomé R, Celli J. Impact of COPD exacerbations on Patient-Centered Outcomes. Chest. 2007:131:696-70.
Courtney BV, Robert JM, Joel DE, Talmadge EK. Murray and Nadal’s text book of respiratory medicine, 4th ed. 2015;36:117-9.
Jadwiga A, Wedzicha G, Donaldson C. Exacerbations of Chronic Obstructive Pulmonary Disease. Respiratory care. 2003;48:12.
Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease thorax. 2002;57(10):847-852.
Hurst JR, Gavin C, Wayomi R, Tom P, Wilkinson MA, John A, et al. Use of Plasma Biomarkers at Exacerbation of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2006;174:867-874.
Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1418-22.
Vestbo J, Prescott E, Almdal T, Dahl M, Nordestgaard BG, Andersen T, et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med. 2006;173(1):79-83.
Pepys MB, Hirschfield, GM. C-reactive protein: a critical update (PDF). J Clin Invest. 2003;111(12):1805-12.
Weis N, Almdal T. C-reactive protein: Can it be used as a marker of infection in patients with exacerbation of chronic obstructive pulmonary disease? Eur J Intern Med. 2006;17(2):88-91.
Austin MA, Wills KE, Bizzard L, Walters EH, Woodbaker. Effect of high flow oxygen in COPD patients in pre-hospital setting RCT. BMJ 2010;341:c5462.
Goldberg A. Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation-a Chest. 1999;116(2):521.
Donaldson GC, Seemungal TAR, Patel IS, Lloyd-Owen SJ, Wilkinson TMA, Wedzicha JA. Longitudinal changes in the nature severity and frequency of COPD exacerbations. R Eur Res. 2003:22: 931-936.
Claudia G. Cote, Luis J, Celli R. Impact of COPD exacerbations on Patient-Centered Outcomes Chest. 2007:131:696-704.
Cote C, Zilberberg MD, Mody SH, Dordelly LJ, Celli B. Haemoglobin level and its clinical impact in a cohort of patients with COPD. Euro Res J. 2007;29(5):923-9.
Perer WR, Hurst JR, Wilkinson RJ, Donaldson GC, Wedzicha JA. Inflammatory changes, recovery and recurrence at COPD exacerbation. ERJ. 2007:29(3):527-34.
